Exhibit 10.1  
EXECUTION VERSION  
SHARE PURCHASE AGREEMENT  
THIS SHARE PURCHASE AGREEMENT (this “Agreement”), dated as of September 26, 2023, by and between ROIVANT SCIENCES LTD. (the “Investor”), a Bermuda exempted limited company, and IMMUNOVANT, INC. (the “Company”), a Delaware corporation. The Investor and the Company are collectively referred to as the “Parties.”  
WHEREAS, the Company intends to conduct an underwritten offering (the “Public Offering”) of shares of its common stock, par value $0.0001 per share (the “Common Shares”) pursuant to an Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and among the Company and certain underwriters (the “Underwriters”), in connection with the Public Offering pursuant to the Company’s Registration Statement on Form S-3 (including the prospectus and prospectus supplement relating to the Public Offering, the “Registration Statement”) that is expected to price after market close on September 27, 2023;  
WHEREAS, the Investor wishes to purchase from the Company, and the Company wishes to issue and sell to the Investor, a number of Common Shares equal to the number of Purchased Shares (as defined below), at a per share price equal to the Public Offering Price (as defined below), under the terms and conditions of this Agreement; and  
WHEREAS, each of the Parties wishes to set forth in this Agreement certain terms and conditions regarding, among other things, the Investor’s ownership of the Common Shares being purchased hereby.  
NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for good and valuable consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows: